RE: Article18 May 2022 10:01
Hopefully the direction (and leadership) of the company will be clarified next Wednesday at the AGM.
One might reasonably expect a boardroom shuffle and a US trial funded by NIH, which together with the overdue Activ2 data set should trigger a stable re-rate. I would not be surprised to see a TR1 posted early next week too (MMs appear to be tree shaking).